30.9.2024

Orphalan and XO Life: Digital therapy support for patients with the rare hereditary disease Wilson's disease

Orphalan and XO Life provide digital support for Wilson's disease patients.

Munich, Germany, September 30, 2024 — Orphalan, an expert in treating Wilson's disease, and XO Life, a leading digital health startup, have decided to work together to improve the treatment and quality of life of patients with Wilson's disease. In addition to drug therapy to treat the hereditary disease, patients can now use XO Life's ImpactMonitor™ platform. After registration, this provides access to validated medical content, personalized insights and enables documentation of the treatment process. Digital support provides patients with a tool for individual treatment support, with which they can also map their therapeutic goals and progress for discussion with the doctor.

Wilson's disease: incurable, usually easy to treat

The rare hereditary disease Wilson's disease, also known as copper storage disease, is not yet curable. However, with early diagnosis and correct and consistent therapy, such as with a chelating agent or zinc, the disease can usually be treated well.

Combined therapy: digital support for patients

By combining digital therapy support with the ImpactMonitor™ platform, which supports daily medication, patients with the hereditary disease Wilson's disease can access additional help available around the clock. They have easy access to validated medical content, can document their treatment course, obtain insights from users compared to other anonymized data, and actively manage their course of treatment.

The systematic recording of one's own patient experiences, so-called patient-reported experiences (PREs) or patient-reported outcomes (PROs), can also be shared with the treating physician. The aim is to further improve adherence, safety of use and treatment success in patients with this chronic disease.

ImpactMonitor™ platform: A new standard in digital healthcare

Sybille Petersohn-Boschmann, Managing Director DACH at Orphalan, explains: “For us as a company, developing and providing innovative solutions for the needs of patients with rare diseases also means using the latest digital technologies. In just three months, we implemented appealing, modern and digital support for our patients with the Mor-bus Wilson disease using XO Life's ImpactMonitor™ platform. ”

“The collaboration not only shows what options XO Life offers with the ImpactMonitor platform™, but also how they can be implemented easily and promptly. Together, we can make an important contribution to the future of healthcare,” says Dr. Friderike Bruchmann, Co-Founder & CEO of XO Life.

About Orphalan

Orphalan is an international company for the development and marketing of medicines for rare diseases headquartered in Paris. Founded in 2011, the company develops and sells innovative therapies for people living with rare and debilitating diseases. The product has been approved for the treatment of Wilson's disease and is available in more than 20 countries.

For more information, visit: www.orphalan.com

About XO Life

With the ImpactMonitor™ platform, XO Life has created a globally unique metaplatform for digital product and therapy support for patients. During their product use or therapy, patients are accompanied with verified medical and health-related content, document their health and treatment progress, receive personalized insights and medical support from experts, and can exchange ideas with others.

Manufacturers can create their own product and therapy areas in the ImpactMonitor™ platform and offer them to their patients with their own branding, content, questions and services. By providing personalized information and continuous support during treatment, manufacturers make an important contribution to treatment success, treatment adherence and application safety.

XO Life works with global market leaders, SMEs and rare disease manufacturers in more than 30 indications. User engagement on the platform is 10 times higher than an average digital health app, and over 120,000 medical questions were answered last year alone. The ImpactMonitor™ platform is now available in all European countries and languages.

‍